TY  - JOUR
A1  - Tsaur, Igor
A1  - Thomas, Anita
A1  - Monecke, Michelle
A1  - Zugelder, Marion
A1  - Rutz, Jochen
A1  - Grein, Timothy
A1  - Maxeiner, Sebastian
A1  - Xie, Hui
A1  - Chun, Felix
A1  - Rothweiler, Florian
A1  - Cinatl, Jindrich
A1  - Michaelis, Martin
A1  - Haferkamp, Axel
A1  - Blaheta, Roman A.
T1  - Amygdalin exerts antitumor activity in taxane-resistant prostate cancer cells
T2  - Cancers
N2  - Despite recent advances in the treatment of metastatic prostate cancer (PCa), resistance development after taxane treatments is inevitable, necessitating effective options to combat drug resistance. Previous studies indicated antitumoral properties of the natural compound amygdalin. However, whether amygdalin acts on drug-resistant tumor cells remains questionable. An in vitro study was performed to investigate the influence of amygdalin (10 mg/mL) on the growth of a panel of therapy-naïve and docetaxel- or cabazitaxel-resistant PCa cell lines (PC3, DU145, and LNCaP cells). Tumor growth, proliferation, clonal growth, and cell cycle progression were investigated. The cell cycle regulating proteins (phospho)cdk1, (phospho)cdk2, cyclin A, cyclin B, p21, and p27 and the mammalian target of rapamycin (mTOR) pathway proteins (phospho)Akt, (phospho)Raptor, and (phospho)Rictor as well as integrin β1 and the cytoskeletal proteins vimentin, ezrin, talin, and cytokeratin 8/18 were assessed. Furthermore, chemotactic activity and adhesion to extracellular matrix components were analyzed. Amygdalin dose-dependently inhibited tumor growth and reduced tumor clones in all (parental and resistant) PCa cell lines, accompanied by a G0/G1 phase accumulation. Cell cycle regulating proteins were significantly altered by amygdalin. A moderate influence of amygdalin on tumor cell adhesion and chemotaxis was observed as well, paralleled by modifications of cytoskeletal proteins and the integrin β1 expression level. Amygdalin may, therefore, block tumor growth and disseminative characteristics of taxane-resistant PCa cells. Further studies are warranted to determine amygdalin’s value as an antitumor drug.
KW  - prostate cancer
KW  - resistant cell lines
KW  - complementary/alternative medicine (CAM)
KW  - amygdalin
KW  - docetaxel
KW  - cabozantinib
KW  - cabazitaxel
Y1  - 2022
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/71454
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-714542
SN  - 2072-6694
N1  - This research was supported by the Brigitta & Norbert Muth Foundation.
VL  - 14
IS  - 13, art. 3111
SP  - 1
EP  - 16
PB  - MDPI
CY  - Basel
ER  -